HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.

Slides:



Advertisements
Similar presentations
Antiretroviral Drug Resistance
Advertisements

Antiretroviral Drug Resistance Anna Maria Geretti UCL Medical School & Royal Free Hampstead Medical School, London.
Effect of intensification of long-term highly active antiretroviral therapy (HAART) with raltegravir on proviral HIV-1 DNA in blood and gut associated.
Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.
New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.
Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
Measuring the latent HIV Reservoir
Unique integration patterns in an in vitro model of HIV-1 latency. Suha M. Saleh, Dimitrios Vatakis, Andrew Harman, Anthony Cunningham, Paul U. Cameron,
Contribution of the immune system to HIV persistence Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine,
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.
Evaluating residual HIV reservoirs Background or why is this important? What can be measured? Where should we measure it? Conclusions.
Main questions on HIV persistence and on obstacles to HIV eradication Jean-Pierre Routy M.D. McGill University Montreal Toward an HIV cure: Insight into.
Instructions To use this template: –for each slide write the correct answer on the orange bar first –choose which option (A,B,C or D) and make sure you.
Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.
1 HIV Curative Strategies: Key Research Priorities Deeks S, et al., (2013) Nat Rev Immunol. 12(8):
Over 50 million HIV/AIDS cases have occurred worldwide Over 40 million people are currently living with HIV/AIDS 95% of all cases are in developing countries.
Alternative RNA splicing in latently infected T cells generates chimeric cellular:HIV mRNAs with the potential to generate Tat and reactivate infection.
EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.
Current HIV basic science research topics. Toddler "Functionally Cured" of HIV Infection- “the Mississippi Baby” First well-documented case of an HIV.
Measuring the latent HIV Reservoir
Strategies for Targeting and Eradicating the HIV Reservoir
David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
Concepts in Basic Science and Translational Research
Latent infection and cellular reservoirs
HIV, CD4, and More Karen Hutcherson Jenn Mann Elizabeth McCauley Michael Powers Courtney Wilson.
Plate 87 Acquired Immune Deficiency Syndrome (AIDS)
Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.
Immune correlates of unusual control of viral replication after cessation of HAART Ellen Van Gulck 1, Leo Heyndrickx 1, Céline Merlin 1, Sandra Coppens.
AIDS supplement. History of HIV Originated in Africa in the late 1950’s Originally found in nonhuman primates and may have mutated First documented in.
Novel Approaches: Treatment and HIV Pathogenesis L. Trautmann, Ph.D. VGTI Florida.
HIV Cellular Pathogenesis III
Evaluation of residual HIV-1 replication among individuals receiving different antiretroviral treatment regimens Giron, LB; Tenore, S; Gabriel, R; Janini,
Characterization of persistent HIV-1 in a broad spectrum of CD4 + T-cells isolated from peripheral blood, bone marrow, lymphoid tissue and gut associated.
1 Modelling the interactions between HIV and the immune system in hmans R. Ouifki and D. Mbabazi 10/21/2015AIMS.
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,
Effect of 24 Week Intensification with a CCR5-Antagonist on the Decay of the HIV-1 Latent Reservoir IAS HIV RESERVOIRS WORKSHOP, 16 & 17 JULY 2010, VIENNA.
Yerkes National Primate Research Center
HIV-1 dynamics Perelson et.al. Science 271:1582 (1996) Infected CD4 + lymphocytes Uninfected, activated CD4 + lymphocytes HIV-1 t 1/ days t 1/2.
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
Myeloid dendritic cells induce HIV-1 latency in non- proliferating CD4 + T cells IAS WORKSHOP, 16 & 17 JULY 2010.
Gui-Qiang Wang Department of Infectious Diseases
Treating HBV Infection: Sustained Remission with Immune control Joseph Sung MD, PhD Department of Medicine and Therapeutics Institute of Digestive Diseases.
Sporadic excesses of unintegrated HIV DNA can occur in HIV+ patients on HAART Una O’Doherty University of Pennsylvania.
Chelsea Harmon Catherine Hanson Abby Llaneza Jen Williams
HIV: Science, Sex and Society. Lecture 2. Strategies for the cure of HIV-1. Mario Stevenson, Ph.D Department of Medicine.
ImmunoPathogenesis of HIV Disease Overview of HIV Epidemic Basic biology of HIV-1 Stages of HIV Disease Viral and Cellular Dynamics after HAART HIV Therapy.
Title Box. “Towards an HIV Cure”: Presentation Outline -Why do we need a cure? -Is a cure feasible and what type of cure can we reach? -Why does HAART.
IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.
The Future of HIV/AIDS: The Road to a Cure. How HIV persists during therapy?  Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun,
Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland Update on HIV Cure Research FORMATTED:
Immune reconstitution Anjie Zhen, PhD
Virsuses: Human Immunodeficiency Syndrome & Acquired Immunodeficiency Syndrome.
2014 “Towards an HIV Cure” symposium Melbourne An Overview of HIV Cure Research in 2014 Diana Finzi, Ph.D. Director, Basic Science Program Division of.
Davey Smith, MD Professor of Medicine University of California San Diego La Jolla, California When Will It All Be Over? HIV Cure Efforts Los Angeles, California:
Alexander Pasternak Laboratory of Experimental Virology, Department of Medical Microbiology Academic Medical Center of the University of Amsterdam Amsterdam,
The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.
State of HIV Cure Research
HIV Cure: Current Status and Future Perspectives
Conflict of Interest No conflicts of interest to declare.
Feedback meeting September 2017
HEATHER Feedback Meeting
AIDS supplement.
Immunodeficiency (2 of 2)
The block-and-lock approach
Why we should ‘shock and kill’
Immunodeficiency (2 of 2)
Alex Sigal, David Baltimore  Cell Host & Microbe 
Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection  Lin Shen, MD, Robert F. Siliciano,
Immunologic strategies for HIV-1 remission and eradication
Presentation transcript:

HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.

Main topics: Implications of plasma viremia Use of antivirals and viremia to model reservoir dynamics The concept of viral latency Homeostatic maintenance of viral DNA Cryptic replication and viral sanctuaries

months on antiviral cocktails (ART) virus particles in plasma (log10) Antiviral treatment: impact on viremia

months on antiviral cocktails (ART) Antiviral treatment: impact on viremia Antiretroviral cocktails cause a 5-6 log reduction in levels of virus in blood within several months of treatment initiation! virus particles in plasma (log10)

What sustains HIV-1 in the face of HAART? Modeling the dynamics of the viral reservoirs!

Faucet = virus source or reservoir Water = virus Drain = virus clearance processes

If there are different faucets or reservoirs, water in each sink empties at different rates

Cellular Reservoirs of HIV-1 Replication and Persistence M. Stevenson Nature Med. 2003

What sustains HIV in the face of therapy? Latent infection of CD4 T-cells or macrophages Homeostatic maintenance of viral DNA Cryptic replication in CD4 T-cells or macrophages Latent infection of CD4 T-cells or macrophages Homeostatic maintenance of viral DNA Cryptic replication in CD4 T-cells or macrophages

What sustains HIV in the face of therapy? Latent infection of CD4 T-cells or macrophages Homeostatic maintenance of viral DNA Cryptic replication in CD4 T-cells or macrophages Latent infection of CD4 T-cells or macrophages Homeostatic maintenance of viral DNA Cryptic replication in CD4 T-cells or macrophages

What is latency? Latency is a reversibly non-productive state of infection. This term describes an infected cell that is not producing virus but that has the capacity to do so under the appropriate conditions.

Courtesy Tae-Wook Chun

The problem with latency! In a latent infection, the virus is inactive- in other words, the only thing that distinguishes the latently infected cell from an uninfected cell is a viral chromosome. Unfortunately, since there is no viral RNA or protein being made, the latently infected cell is invisible to the immune system or to the antiviral drugs. In addition, the CD4 T-cell is long-lived!

Time on HAART (years) Latent Cell Frequency Slow decay of latently infected CD4 + T cells Time to eradication > 73.4 years Courtesy Bob Siliciano

What sustains HIV in the face of therapy? Latent infection of CD4 T-cells or macrophages Homeostatic maintenance of viral DNA Cryptic replication in CD4 T-cells or macrophages Latent infection of CD4 T-cells or macrophages Homeostatic maintenance of viral DNA Cryptic replication in CD4 T-cells or macrophages

Mechanisms of HIV persistence T cell survival Homeostatic proliferation Finzi et al. Science 1997 ; Wong et al. Science 1997 ; Chun et al. PNAS 1997 ; Palmer et al. PNAS 2008 ; Chomont et al. Nat Med 2009 Latent reservoir

Mechanisms of HIV persistence T cell survival Homeostatic proliferation Finzi et al. Science 1997 ; Wong et al. Science 1997 ; Chun et al. PNAS 1997 ; Palmer et al. PNAS 2008 ; Chomont et al. Nat Med 2009 Latent reservoir Homeostatic proliferation may maintain dead viruses! 6% of human DNA comprises dead ancestral viruses! This poses a problem when trying to determine if an individual has been cured! Homeostatic proliferation may maintain dead viruses! 6% of human DNA comprises dead ancestral viruses! This poses a problem when trying to determine if an individual has been cured!

Size of latent reservoir VOA Intact HIV DNA Scale=100/ fold Ho et al, Cell, 2013

What sustains HIV in the face of therapy? Latent infection of CD4 T-cells or macrophages Homeostatic maintenance of viral DNA Cryptic replication in CD4 T-cells or macrophages Latent infection of CD4 T-cells or macrophages Homeostatic maintenance of viral DNA Cryptic replication in CD4 T-cells or macrophages

Multiple viral RNA species produced in infected cells

Multiple forms of viral RNA – prematurely terminated, spliced, unspliced – produced in infected cells. CA-RNA present in infected cells from individuals on suppressive ART (Furtado NEJM, 2009; Yerly JID, 2009; Hockett J. Exp. Med, 1999) CA-RNA predicts time to rebound post-treatment interruption Multiple forms of viral RNA – prematurely terminated, spliced, unspliced – produced in infected cells. CA-RNA present in infected cells from individuals on suppressive ART (Furtado NEJM, 2009; Yerly JID, 2009; Hockett J. Exp. Med, 1999) CA-RNA predicts time to rebound post-treatment interruption

ART de-intensification studies Rothenberger et al., PNAS. March 2015

Baseline reservoir size and timing of viral rebound Jonathan Li

If there is some residual viral activity, how could this occur in the face of such powerful antiviral forces? There may be anatomic sites that act as sanctuaries for the virus

Reservoirs of HIV-1 persistence in HAART M. Stevenson, Scientific American 2008

Reservoirs of HIV-1 persistence in HAART M. Stevenson, Scientific American 2008 Drugs may not access all tissues with equal efficiency. This could create sanctuaries!

Sanctuaries for viral replication?

✖ ✖ ✖

ART intensification studies

In infected individuals on potent therapy, are the drugs completely shutting off the faucet?